| Psoriasis vulgaris
Siliq vs Abrilada
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Siliq vs Abrilada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAbrilada has a higher rate of injection site reactions vs Siliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Abrilada but not Siliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Siliq
Abrilada
At A Glance
Subcutaneous
Every 2 weeks
IL-17RA antagonist
SC injection
Every 1-2 weeks
TNF-alpha blocker
Indications
- Psoriasis vulgaris
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis vulgaris
- Hidradenitis Suppurativa
- Uveitis
Dosing
Psoriasis vulgaris 210 mg subcutaneously at Weeks 0, 1, and 2 followed by 210 mg every 2 weeks.
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile polyarthritis Weight-based SC dosing every other week for patients 2 years of age and older: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), 40 mg (>=30 kg).
Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years: weight-based induction then 20 mg every other week (<40 kg) or 40 mg every other week (>=40 kg) starting Day 29.
Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Week 8 (Day 57).
Psoriasis vulgaris, Uveitis 80 mg SC initial dose, then 40 mg every other week starting one week after the initial dose.
Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.
Contraindications
- Crohn's disease
- Clinically significant hypersensitivity to brodalumab or to any of the excipients
—
Adverse Reactions
Most common (>=1%) Arthralgia (4.7%), headache (4.3%), fatigue (2.6%), diarrhea (2.2%), oropharyngeal pain (2.1%), nausea (1.9%), myalgia (1.7%), injection site reactions (1.5%), influenza (1.3%), neutropenia (1.0%), tinea infections (1.0%).
Serious Suicidal ideation and behavior (0.37 per 100 subject-years), infections including fungal infections, neutropenia grade >=3.
Postmarketing Hypersensitivity reactions, anaphylaxis including anaphylactic shock, pruritus, rashes, eczema, urticaria, dermatitis, eczematous eruptions (atopic dermatitis-like eruptions).
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, accidental injury, nausea, urinary tract infection, sinusitis, hyperlipidemia, flu syndrome, abdominal pain, back pain, hypercholesterolemia, hypertension
Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, malignancies, hepatitis B reactivation, demyelinating disorders, hematologic reactions, heart failure, autoimmunity
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, systemic vasculitis, deep vein thrombosis
Pharmacology
Brodalumab is a human monoclonal IgG2 antibody that selectively binds to IL-17RA and inhibits its interactions with IL-17 family cytokines (IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, IL-25), thereby blocking IL-17 cytokine-induced pro-inflammatory responses.
Adalimumab-afzb is a recombinant human IgG1 monoclonal antibody TNF-alpha blocker that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammation and modulating TNF-induced biological responses including leukocyte migration.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Siliq
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Abrilada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Siliq
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Abrilada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Siliq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Abrilada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$50/momo
Siliq Solutions Instant Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Abrilada.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbriladaView full Abrilada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.